188 related articles for article (PubMed ID: 19218915)
1. Erlotinib-induced pustular eruption.
Cusano F; Ferrara G; Barletta E; Ingordo V
G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
3. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
4. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
5. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Ong CK; Tan WC; Chan LC; Abdul Razak M
Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
[TBL] [Abstract][Full Text] [Related]
7. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
8. An acneiform eruption due to erlotinib: prognostic implications and management.
Journagan S; Obadiah J
J Am Acad Dermatol; 2006 Feb; 54(2):358-60. PubMed ID: 16443077
[No Abstract] [Full Text] [Related]
9. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
10. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
13. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Campbell TM; Brown CW
J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
[TBL] [Abstract][Full Text] [Related]
14. Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Lin TC; Wu PY
Cutis; 2011 Dec; 88(6):281-3. PubMed ID: 22372166
[No Abstract] [Full Text] [Related]
15. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
16. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
[TBL] [Abstract][Full Text] [Related]
19. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
[TBL] [Abstract][Full Text] [Related]
20. The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Wojas-Krawczyk K; Krawczyk P; Mlak R; Kucharczyk T; Kowalski DM; Krzakowski M; Milanowski J
Respiration; 2011; 82(4):341-50. PubMed ID: 21242665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]